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Abstract
Background: Many age-associated disorders (including diabetes, cancer, and neurodegenerative diseases) are linked to
mitochondrial dysfunction, which leads to impaired cellular bioenergetics and increased oxidative stress. However, it is not
known what genetic and molecular pathways underlie differential vulnerability to mitochondrial dysfunction observed
among different cell types.
Methodology/Principal Findings: Starting with an insulinoma cell line as a model for a neuronal/endocrine cell type, we
isolated a novel subclonal line (named CRI-G1-RS) that was more susceptible to cell death induced by mitochondrial
respiratory chain inhibitors than the parental CRI-G1 line (renamed CRI-G1-RR for clarity). Compared to parental RR cells, RS
cells were also more vulnerable to direct oxidative stress, but equally vulnerable to mitochondrial uncoupling and less
vulnerable to protein kinase inhibition-induced apoptosis. Thus, differential vulnerability to mitochondrial toxins between
these two cell types likely reflects differences in their ability to handle metabolically generated reactive oxygen species
rather than differences in ATP production/utilization or in downstream apoptotic machinery. Genome-wide gene expression
analysis and follow-up biochemical studies revealed that, in this experimental system, increased vulnerability to
mitochondrial and oxidative stress was associated with (1) inhibition of ARE/Nrf2/Keap1 antioxidant pathway; (2) decreased
expression of antioxidant and phase I/II conjugation enzymes, most of which are Nrf2 transcriptional targets; (3) increased
expression of molecular chaperones, many of which are also considered Nrf2 transcriptional targets; (4) increased expression
of b cell-specific genes and transcription factors that specify/maintain b cell fate; and (5) reconstitution of glucose-
stimulated insulin secretion.
Conclusions/Significance: The molecular profile presented here will enable identification of individual genes or gene
clusters that shape vulnerability to mitochondrial dysfunction and thus represent potential therapeutic targets for diabetes
and neurodegenerative diseases. In addition, the newly identified CRI-G1-RS cell line represents a new experimental model
for investigating how endogenous antioxidants affect glucose sensing and insulin release by pancreatic b cells.
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Introduction
Mitochondrial dysfunction has multifactorial etiology. In rare
but severe inherited mitochondrial disorders (which typically
present in childhood or early adulthood and affect metabolically
active organs such as the brain, heart, liver, and skeletal muscle),
mitochondrial dysfunction is a result of germline mutations in
nuclear or mitochondrial DNA. In contrast, accumulation of
somatic mitochondrial DNA mutations that accompanies aging or
an impairment in mitochondrial function caused by metabolic and
environmental factors are thought to contribute to the pathogen-
esis of many common age-associated disorders including diabetes,
cancer, and neurodegeneration [1]. In diabetes, impaired
mitochondrial metabolism contributes to insulin resistance ob-
served in peripheral tissues [2,3], in part through increase in the
level of reactive oxygen species (ROS) [4]. There is also
accumulating evidence that mitochondrial dysfunction blunts
glucose-stimulated insulin secretion (GSIS) in pancreatic b cells.
In a b cell line, for example, GSIS is inhibited following depletion
of native mitochondrial DNA and can be restored by repopulation
of cybrid cells with foreign mitochondrial DNA [5]. Similarly,
GSIS impairment caused by a partial loss of the pancreatic
transcription factor PDX-1 (heterozygosity of which leads to a
form of the maturity-onset diabetes of the young) is mediated by
changes in the mitochondrial gene expression [6,7]. While it is
currently not understood how mitochondrial dysfunction leads to
the GSIS impairment, changes in the ROS metabolism are an
important candidate because mitochondrially produced ROS act
as a signal both in the hypothalamic glucose sensing [8] and the b
cell GSIS [9].
Given that mitochondrial dysfunction plays an important role in
the pathogenesis of both diabetes and neurodegeneration, it is
perhaps not surprising that epidemiologic studies have shown a
link between the two [10]. For example, it is well established that
patients with diabetes have an increased risk of dementia and/or
Alzheimer’s disease (reviewed in [11]). To further dissect the
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patients into subcategories depending on the severity and duration
of diabetes on one hand and the subtype of dementia on the other.
In one such prospective cohort study, diabetes overall was
associated with increased risk of vascular dementia, while
borderline and undiagnosed diabetes were associated with
increased risk of Alzheimer’s disease [12]. In another prospective
study, higher risk of Alzheimer’s disease was associated not with
low insulin sensitivity but with low early insulin response to oral
glucose challenge, a measure of insulin release [13]; this finding, in
particular, raises the possibility that the link between the two
diseases reflects an intracellular signaling defect in a pathway
common to neurons and pancreatic b cells. A link between
diabetes and Parkinson’s disease is also suggested by the
epidemiologic literature, but its nature is currently unclear: case
control studies performed thus far mostly showed that diabetes was
associated with a decreased risk of Parkinson’s disease, while
prospective cohort studies either showed that diabetes was
associated with an increased risk of Parkinson’s disease or that
there was no association between the two diseases ([14]; [15] and
references therein). The discrepancy between these results raises
the possibility that – like Alzheimer’s disease – Parkinson’s disease
is not associated with the diabetic state per se, but with some
underlying metabolic or signaling abnormality that is shared
between neurons and b cells. While additional epidemiologic
studies with better patient stratification are required to clarify the
connections between diabetes and Parkinson’s disease, together
these studies underscore the underlying biological similarities
between neurons and b cells and highlight the importance of
identifying shared signaling pathways that modulate susceptibility
to mitochondrial dysfunction in neuroendocrine cells.
Here, two subclones of an insulinoma cell line that differ in the
susceptibility to mitochondrial and oxidative stressors were used to
identify gene expression changes associated with vulnerability to
mitochondrial dysfunction in the neuronal/endocrine cell type.
Results
Isolation of a CRI-G1 cell line subclone that shows
increased vulnerability to mitochondrial and oxidative
stress
CRI-G1 is one of four cell lines isolated from a transplantable
Cambridge Rat Islet cell tumor in 1985 [16]. CRI-G1 cells are
rounded, have slender processes, and grow in clumps and ribbons
rather than forming an epithelial monolayer ([16] and Fig. 1A).
When maintained in culture for extended periods of time,
however, CRI-G1 cells flatten and become more epithelioid in
appearance (Fig. 1B); this transition is stochastic in nature, but can
be facilitated by growing cells at high densities. The differences
between the two CRI-G1 cell subtypes are not restricted to
morphology, however: compared to the parental clone, which is
resistant to cell death induced by mitochondrial complex I
inhibitor rotenone, the novel CRI-G1 cell subclone (which we
cryopreserved as a separate cell line after one of the stochastic
transition events) is highly susceptible to this mitochondrial toxin,
with 51.463.6% loss of viability and ,3 fold increase in release of
an intracellular protease (marker of cell death) following an
overnight treatment with a 1 mM rotenone (Figs. 2A and B). [In
this and all subsequent figures, the original clone is termed CRI-
G1-RR (for Rotenone-Resistant) and the novel subclone CRI-G1-
RS (for Rotenone-Susceptible).] Similar results were seen with
longer treatments (up to 5 days) and higher doses of rotenone (up
to 10 mM; not shown).
To determine whether CRI-G1-RS cell line is more susceptible
to cell death in general, we tested two additional mitochondrial
toxins (complex III inhibitor antimycin and complex V inhibitor
oligomycin) as well as staurosporine, a protein kinase inhibitor and
potent apoptosis inducer. Interestingly, CRI-G1-RS cells were
more susceptible to both antimycin- (Figs. 2C and D) and
oligomycin-induced cell death (Figs. 2E and 2F), but less
susceptible to staurosporine-induced apoptosis (Figs. 2G and H).
Of the three mitochondrial inhibitors tested, antimycin was most
toxic to CRI-G1-RS cells (maximal viability loss of 59.963.7%),
but no mitochondrial toxin led to 100% CRI-G1-RS cell loss
regardless of the length of the treatment (up to 5 days) or the dose
used (data not shown). In contrast, the maximal dose of
staurosporine (1 mM) was completely toxic to both cell types, with
lower susceptibility of CRI-G1-RS cells apparent only in the mid-
range part of the dose-response curve (Fig. 2G). Consistent with
the cell viability data, the increase in caspase 3/7 activity was
greater in CRI-G1-RR than in CRI-G1-RS cells at these mid-
range doses (100 and 300 nM; Fig. 2H). The three mitochondrial
inhibitors led to only minimal activation of caspase 3/7 in both cell
types (data not shown), suggesting that in this experimental system
cell death induced by mitochondrial inhibition is largely non-
apoptotic in nature.
In general, mitochondrial inhibition leads to (1) a decrease in
ATP synthesis, eventually resulting in ATP depletion and (2) an
Figure 1. Morphology of CRI-G1 cell lines. A. Parental CRI-G1 cells are rounded, have slender processes, and grow in clumps and ribbons rather
than forming an epithelial monolayer. In subsequent text and figures, this phenotype is termed CRI-G1-RR (for explanation of the nomenclature, see
Results section.) B. Prolonged culturing at high density conditions leads to a preponderance of cells with surface-adherent, epithelioid appearance
that grow in clusters or islands. In subsequent text and figures, this phenotype is termed CRI-G1-RS. Images were acquired by differential interference
contrast (DIC) microscopy of living cultures; scale bar, 50 mM.
doi:10.1371/journal.pone.0014485.g001
Metabolic Stress Vulnerability
PLoS ONE | www.plosone.org 2 January 2011 | Volume 6 | Issue 1 | e14485Figure 2. Differential vulnerability to mitochondrial inhibition and staurosporine-induced apoptosis. CRI-G1-RS cells are more
vulnerable to cell death induced by mitochondrial respiratory chain inhibitors rotenone (panels A and B), antimycin (panels C and D), and oligomycin
(panels E and F), but less vulnerable to apoptosis induced by protein kinase inhibitor staurosporine (panels G and H). Cell viability (panels A, C, E and
G) was measured by CellTiter 96 AQueous One Solution Cell Proliferation Assay (‘‘MTS assay’’), a variant of the classic MTT assay; averaged data from 3–
6 repeat experiments are shown in each panel. Cell death (panels B, D, and F) was determined by CytoTox-Glo
TM Assay, which measures the activity of
a ‘‘dead-cell’’ protease released into the media from membrane-compromised cells; a representative of at least 3 repeat experiments is shown in each
panel (n=4 in each experiment). Caspase 3/7 activity, an indicator of apoptosis, was measured by Caspase-Glo
TM 3/7 Assay (panel H); a representative
of 3 repeat experiments is shown (n=4 in each experiment). Although MTS assay is based on mitochondrial metabolism and thus could be directly
affected by mitochondrial inhibitors, there was a good correspondence between viability and cell death assay results for all compounds tested.
Statistical significance was determined by two-way ANOVA, which showed highly significant effect of both treatment and cell type in all conditions
tested. Data are plotted as mean 6 S.E.M.; ***, p,0.001.
doi:10.1371/journal.pone.0014485.g002
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respiratory chain activity; the relative magnitude of each effect
depends on the specific respiratory chain complex targeted by the
inhibitor and the inhibitor concentration used [17]. To determine
whether increased vulnerability to mitochondrial inhibition seen in
CRI-G1-RS cell line is due to a diminished ability to cope with
ATP depletion or to increased vulnerability to oxidative stress, we
examined the susceptibility of both cell types to cell death induced
by mitochondrial uncoupler FCCP (which leads to mitochondrial
depolarization and ATP depletion in the absence of significant
ROS production [18,19]) or by ROS-generating hypoxanthine/
xanthine oxidase (HX/XO) system (which results in oxidative
stress with no direct effect on ATP production [20]). FCCP was
equally toxic to both cell types at all doses tested (Fig. 3A),
suggesting that there was no difference between the two cell lines
in their ability to produce (or use) ATP. Consistent with this
finding, the total mitochondrial mass (determined by immuno-
blotting for mitochondrial proteins Tom20 and cytochrome c;
Supplemental Figs. S1-A and S1-B) did not differ between CRI-
G1-RR and -RS cells. (Interestingly, the level of CoxIV – a
subunit of mitochondrial complex IV – was 2.24 fold higher in RS
cells relative to RR cells [n=8, p,0.0001], suggesting an increase
in expression of respiratory chain proteins without change in the
overall number of mitochondria in this cell type; Supplemental
Fig. S1-C.) In contrast, CRI-G1-RS cells were significantly more
susceptible to oxidative stress generated by HX/XO treatment
(Fig 3B). This effect was dose dependent, with the greatest
difference observed at 16 U/L of XO (in the presence of 0.5 mM
HX): following overnight treatment, the residual viability at this
dose – the second largest tested – was 84.6612.0% for RR cells
but only 14.163.9% for RS cells.
To further evaluate the differences in susceptibility to oxidative
stress between RR and RS cells, 1 h treatment with 0.5 mM HX/
16 U/L of XO (or vehicle) was followed by immunostaining for 4-
hydroxynonenal (4-HNE), a lipid peroxidation product and a
marker of the oxidative stress ([21]; Fig. 4A), or by measurement of
glutathione (GSH) and glutathione disulfide (GSSG) levels
(Figs. 4B, 4C and S2). RR cells showed significant 4-HNE
immunoreactivity at baseline (Fig. 4A-a), but no increase in
staining following the HX/XO treatment (Fig. 4A-b). In contrast,
baseline 4-HNE immunoreactivity in RS cells was barely
detectable (Fig. 4A-c), but staining intensity strongly increased
following 1 h exposure to HX/XO (Fig. 4A-d). The concentration
of total GSH (Fig. 4B) was higher in RR than in RS cells both at
baseline (9.661.4 vs. 2.860.5 nmol/mg protein; n=4, p,0.001)
and after HX/XO treatment (6.060.3 vs. 2.160.7 nmol/mg
protein; n=3, p,0.05; Fig. 4B); interestingly, oxidant treatment
resulted in a statistically significant decrease in the total GSH
concentration in RR cells only (p,0.001). The GSH/GSSG ratio,
which is an indicator of the cellular redox potential, did not
significantly differ between RR and RS cells at baseline (2.761.0
vs. 4.961.5; n=4). Following the HX/XO treatment, the GSH/
GSSG ratio did not significantly change in RS cells (from 4.961.5
to 3.660.9; n=3); in RR cells it paradoxically increased (from
2.761.0 to 11.662.4; n=4, p,0.01), resulting in a statistically
significant difference between the two cell types under oxidizing
conditions (p,0.05). The increase in the GSH/GSSG ratio
observed in RR cells after oxidant exposure is a result of a decrease
in the concentration of GSSG rather than an increase in the
concentration of GSH (Supplemental Fig. S2); this is likely due to
an increase in the GSSG efflux that can complicate interpretation
of GSH/GSSG ratio under oxidizing conditions [22]. Taken
together, these results indicate that, compared to the parental
CRI-G1-RR cells, CRI-G1-RS cells are in a relatively reduced
state at baseline, but are more vulnerable to injury and cell death
when exposed to oxidative stress. In addition, the data suggest that
increased vulnerability of CRI-G1-RS cells to mitochondrial
inhibition is primarily a result of the lesser capacity to handle
metabolically generated ROS.
Expression profiling
CRI-G1-RR and RS cell lines are closely related, but show
large differences in susceptibility to mitochondrial and oxidative
stressors; this enabled us to use genome-wide gene expression
analysis to uncover a molecular profile associated with vulnera-
bility to mitochondrial dysfunction. Biotinylated cRNA probes (six
independent biological replicates for each cell type) were
hybridized to rat Affymetrix 230 2.0 arrays, which contain
31100 oligonucleotide probes representing 14318 unique genes.
The statistical analysis showed that 12872 probes, corresponding
to 5861 unique genes, showed statistically significant differential
Figure 3. Differential vulnerability to ATP depletion and
oxidative stress. A. CRI-G1-RR and RS cells are equally vulnerable to
mitochondrial uncoupler FCCP, which leads to ATP depletion. B. CRI-
G1-RS cells are more vulnerable than RR cells to oxidative stress induced
by co-application of hypoxanthine and xanthine oxidase. Cell viability
was measured by CellTiter 96 AQueous One Solution Cell Proliferation
Assay, a variant of the classic MTT assay; an average of 3 repeat
experiments is shown in each panel. Statistical significance was
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of 999 probes (corresponding to 550 unique genes) showed a large
difference in expression ($2 fold); out of these 550 genes, 216 were
upregulated (log2fold change from 1 to 4.89) and 334 downreg-
ulated (log2fold change from 21t o25.57) in oxidative stress-
vulnerable CRI-G1-RS cells (Fig. 5A). Unsupervised hierarchical
clustering was performed using 999 probes with differential
expression $2 fold (Fig. 5B), top 25 genes upregulated in RS
cells (by p-value; Fig. 5C), and top 25 genes downregulated in RS
cells (also by p-value; Fig. 5D). In all three analyses, independent
biological replicates of each cell type clustered together, indicating
that phenotypic differences we identified correspond to specific
transcriptional profiles. (The same was true when analysis was
performed using all probes on the array; data not shown.)
Twenty genes from biologically interesting pathways (discussed
further in the next section) were chosen for validation of
microarray data by qRT-PCR; of these 20 genes, 10 were
downregulated (log2fold change range -0.27 to 25.50) and 8
upregulated (log2fold change range 0.40 to 1.26) in RS cells, while
2 showed no statistically significant change in expression between
the two cell types (Table 1). The quantitative correlation between
the microarray and qRT-PCR data was much better for
downregulated genes (r
2=0.96, p,0.0001; Supplemental Fig.
S3-A) than for upregulated genes (r
2=0.11, p=0.59; Supplemen-
tal Fig. S3-B). Given that independent biological replicates were
used for each method, these differences could reflect the pathway-
specific accumulation of additional gene expression changes.
Alternatively, there may be inherent differences between the two
methods that are unevenly distributed across the gene expression
spectrum. Nonetheless, the overall correspondence between the
two methods was good, with 9 of 10 downregulated genes and 8 of
8 upregulated genes showing statistically significant differential
expression and the same direction of expression changes in both
experimental paradigms (Table 1); this degree of correspondence
is within the range generally described in the literature.
To identify pathways that might underlie increased vulnerability
to mitochondrial and oxidative stress in CRI-G1-RS cells, we
analyzed gene expression data using GOstat [23] and Ingenuity
Pathways Analysis (IPA version 7.6; IngenuityH Systems, www.
ingenuity.com). GOstat analysis, performed on 999 probes that
showed $2 fold change in expression in either direction, identified
53 significant GO annotations (based on an FDR adjusted p-value
cutoff of 0.05; Supplemental Table S1). While these 53 GO
annotations included a number of different biological processes,
the two most common categories were cell metabolism (9 of 53
Figure 4. Differential handling of ROS at baseline and
following oxidative challenge. A. Immunofluorescence staining
for lipid peroxidation marker 4-HNE (green) shows that baseline ROS
level is higher in RR cells (a) than in RS cells (b). After treatment with
HX/XO, an increase in 4-HNE staining is seen in RS cells (d) but not in RR
cells (c). Nuclei are visualized by DAPI counter stain (blue). Images were
acquired by confocal microscopy; scale bars: 50 mm, main panels;
20 mm, insets. A representative of .3 independent experiments is
shown. B. Total GSH level is higher in RR than RS cells both at baseline
and after HX/XO treatment; the oxidative challenge significantly
decreased total GSH in RR cells only. C. GSH/GSSG ratio is not
significantly different between RR and RS cells at baseline. Following
HX/XO treatment, it increased in RR cells but did not change in RS cells,
resulting in a significant difference between the two cell types. In all
experiments, HX/XO treatment consisted of 0.5 mM HX and 16 U/L XO
and was applied for 1 h. In B and C, statistical significance was
determined by two-way ANOVA followed by ad-hoc Bonferroni




PLoS ONE | www.plosone.org 5 January 2011 | Volume 6 | Issue 1 | e14485Figure 5. Analysis of gene expression data. A. The volcano plot shows that there are many significant genes with high fold change; significant
genes (probes with FDR adjusted p-values,0.05) with differential expression $2 fold are marked in red. B–D. Unsupervised hierarchical clustering
shows that independent biological replicates of each cell type group together (high expressing genes, red; low expressing genes, green). The
analyses were performed using 999 probesets with differential expression $2 fold (panel B), top 25 genes upregulated in RS cells (by p-value; panel
C), and top 25 genes downregulated in RS cells (also by p-value; panel D). In panels C and D, black font is used for gene symbols identified by the
Metabolic Stress Vulnerability
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25 to 0.04) and neuronal
differentiation or function (another 9 of 53 annotations; p-value
range 8.87610
25 to 0.03). Other potentially interesting GO
annotations included ER-nuclear signaling pathway (GO ID:
0006984; p=0.01); response to stress (GO ID: 0006950; p=0.03);
and unfolded protein response (GO ID: 0030968; p=0.03).
Ingenuity Pathways Analysis was performed on an expanded
probe set (3917 probes with FDR-adjusted p-value#0.001,
regardless of the fold change; when multiple probes were present
for a single gene, the probe with the smallest p-value was used).
The top five Physiological System Development and Function gene
network clusters identified by this analysis were Endocrine System
Development and Function cluster (p-value range 0.0002 to 0.05),
Tissue Morphology cluster (p-value range 0.0002 to 0.05),
Connective Tissue Development and Function cluster (p-value
range 0.002 to 0.05), Nervous System Development and Function
cluster (p-value range 0.007 to 0.05), and Skeletal and Muscular
System Development and Function cluster (p-value range 0.01 to
0.05). Ingenuity Pathways Analysis can also be used to identify
canonical pathways that show statistically significant ratio of
differentially expressed genes; the top five Canonical Pathways
identified by IPA in our dataset were Nrf2-mediated Oxidative
Stress Response (p-value=6.73610
25); FAK (Focal Adhesion
Kinase) Signaling (p-value=2.54610
23); EIF2 (Elongation Initi-
ation Factor 2) Signaling (p-value=3.84610
23); Integrin Signal-
ing (p-value=3.94610
23); and Galactose Metabolism (p-val-
ue=4.16610
23). Taken together, these data show that a
relatively large number of genes is differentially expressed between
CRI-G1-RR and CRI-G1-RS cells and that these genes are
involved in a number of distinct biological pathways; gene
Table 1. qRT-PCR validation of microarray data for selected genes.
Gene









Gpx2 Glutathione peroxidase 2 1374070_at 25.4946 4.17E-15 25.4842 ,0.0001
Nqo2 NAD(P)H dehydrogenase,
quinone 2
1374959_at 23.0212 1.87E-14 23.4518 ,0.0001
Ephx1 Epoxide hydrolase 1,
microsomal
1387669_a_at 22.3098 1.29E-11 23.1377 ,0.0001
Txnrd1* Thioredoxin reductase 1 1386958_at 21.8186 4.98E-09 22.1232 ,0.0001
Nqo1 NAD(P)H dehydrogenase,
quinone 1
1387599_a_at 21.7330 1.30E-08 22.0396 ,0.0001
Gclc* Glutamate-cysteine ligase,
catalytic subunit
1372523_at 21.3981 1.75E-10 21.5696 ,0.0001
Ucp2 Uncoupling protein 2
(mitochondrial, proton
carrier)
1368669_at 21.1069 4.75E-09 20.7164 0.0011
Nfe2l2 Nuclear factor, erythroid
derived 2
1367826_at 20.4808 1.04E-04 20.2784 0.3640
Park7 Parkinson disease (autosomal
recessive, early onset) 7
1368653_a_at 20.4464 5.87E-07 20.5447 0.0047
Gclm Glutamate cysteine ligase,
modifier subunit
1370030_at 20.2666 4.14E-03 20.5451 0.0035
Nkx6-1 NK6 homeobox 1 1368998_at 1.2551 6.21E-09 3.1688 0.0003
Pax4 Paired box 4 1370140_a_at 1.5244 3.52E-09 1.8654 0.0009
Pdx1 Pancreatic and duodenal
homeobox 1
1369516_at 1.1104 9.58E-09 1.0633 0.0019
Ins2 Insulin 2 1370077_at 1.0955 1.51E-06 not detectable
in RR samples
n.a.
Neurod1 Neurogenic differentiation 1 1387288_at 0.8884 5.07E-09 1.6602 0.0001
Keap1 Kelch-like ECH-associated
protein 1
1370066_at 0.4625 2.46E-07 0.7266 0.0004
Ins1 Insulin 1 1387815_at 0.4069 1.63E-05 3.7082 ,0.0001
Gck Glucokinase 1387312_a_at 0.4007 3.34E-05 4.3504 0.0003
Txn1 Thioredoxin 1 1398839_at 0.0446 0.3041 20.0122 0.9246
Me1 Malic enzyme 1,
NADP(+)-dependent,
cytosolic
1370067_at 0.0645 0.4560 0.3880 0.0046
Ins2 mRNA was not detectable in RR samples using qRT-PCR; thus, log2fold change and p-value could not be calculated for this gene. For genes marked with *, multiple
probes were present on the array; the table lists a probe showing the greatest fold change.
doi:10.1371/journal.pone.0014485.t001
Affymetrix array profile and blue font for gene symbols identified by manual BLAST search with Affymetrix source sequences. Unknown gene in panel
C corresponds to Affymetrix probe 1385716_at (source sequence AW522166).
doi:10.1371/journal.pone.0014485.g005
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mitochondrial and oxidative stress are discussed in more detail in
the next section.
Expression changes in antioxidant and detoxifying
enzyme genes
Among top 25 genes downregulated in RS cells (based on p-
value; Fig. 5D), three genes (Gpx2, Mgst2_predicted, and Nqo1) are
downstream targets of Nrf2 (nuclear factor-erythroid 2-related
factor 2). Nrf2 is a transcription factor that regulates both baseline
and inducible expression of a battery of molecular chaperons,
antioxidant, and phase I/II conjugation enzymes in a number of
organs including the lung, liver and brain [24]; its function in
pancreatic b cells, however, is not well understood. The analysis of
gene expression changes for the entire Nrf2 pathway, performed
by IPA, showed that many Nrf2 target genes (75 of 185) were
differentially expressed between CRI-G1-RR and CRI-G1-RS
cells (Fig. 6; larger version is provided as Supplemental Fig. S4); for
a subset of these genes (Gpx2, Nqo2, Ephx1, Txnrd1, Nqo1, Gclc, and
Gclm), we confirmed the microarray-identified expression changes
by qRT-PCR (Table 1). Interestingly, while Nrf2-regulated
antioxidant and detoxifying (phase I/II conjugating) enzymes
were downregulated in RS cells, Nrf2-regulated molecular
chaperones (including members of Hsp22, 40 and 90 families)
were largely upregulated in the same cell type; the basis for this
differential regulation of distinct subsets of Nrf2 target genes is
currently unclear.
To further delineate differences in Nrf2 pathway regulation
between RR and RS cells, we determined the mRNA and protein
expression levels of Nrf2 and its regulator Keap1 (Kelch-like ECH-
associated protein 1). Under baseline conditions, Nrf2 is bound to
actin cytoskeleton by Keap1, which prevents its translocation into
the nucleus and targets it for ubiquitination and proteosomal
degradation. In response to oxidative stress, kinase activation, or
small molecule activators such as tert-butylhydroquinone (tBHQ)
and sulforaphane (SF), Nrf2 is stabilized and translocates into the
nucleus, where it binds the antioxidant response element (ARE)
sequences in the promoter of its target genes and activates their
transcription (reviewed in [24,25]). We also determined mRNA
and protein expression levels of DJ-1, which regulates Nrf2
stability in fibroblasts and the lung or lung-derived cell lines
[26,27], but not in neurons or astrocytes [28]. DJ-1 is a redox-
sensitive protein [29,30], mutations in which have been linked to
an autosomal recessive form of Parkinson’s disease [31]; it has
recently been shown to protect b cells from various stress
conditions [32]. The microarray data showed a modest but
statistically significant decrease in expression of Nrf2 mRNA
(Nfe2l2; log2fold change=20.48, p-value=0.0001); however, this
finding was not confirmed by qRT-PCR (log2fold change=20.28,
p-value=0.36; Table 1). Nonetheless, the expression of transcrip-
tionally-active Nrf2 protein (assessed by immunoblotting of
nuclear fractions with anti-Nrf2 antibody; Fig. 7A) was signifi-
cantly lower in RS than in RR cells (53% or ,2 fold decrease;
n=8, p,0.0001). In cytoplasmic fractions, Nrf2 protein level was
below detection threshold in either cell type (data not shown).
Significant differences in protein expression without major
changes in mRNA expression suggest that regulation primarily
occurs on the post-translational level. Consistent with this
possibility, we found that RR and RS cells expressed different
levels of Keap1 and DJ-1. Specifically, Keap1 was significantly
upregulated in RS cells both on mRNA (microarray: log2fold
change=0.46, p-value=2.46610
27; qRT-PCR: log2fold
change=0.73, p-value=0.0004; Table 1) and protein levels
(35.6% or 1.36 fold increase; n=10, p,0.05; Fig. 7B). In contrast,
the expression of DJ-1/Park7 mRNA (microarray: log2fold
change=20.45, p-value=5.87610
27; qRT-PCR: log2fold
change=0.54, p-value=0.005; Table 1) and protein (31.5% or
1.46 fold decrease; n=7, p=0.0002; Fig. 7C) was significantly
decreased in RS cells. Given the reciprocal functions of Keap1 and
DJ-1 in the regulation of Nrf2 pathway, both of these changes
would be expected to result in destabilization of Nrf2 protein and
subsequent downregulation of Nrf2 target genes in RS cells, as
observed in the microarray and qRT-PCR datasets. Interestingly,
treatment with 5 mMS Fo r1 0mM tBHQ for either 8 h (Fig. 7D)
or 16 h (Fig. 7E) upregulated nuclear Nrf2 expression to the same
extent in both RR and RS cells despite the baseline differences in
Nrf2 pathway activity between the two cell types. (Visualizing low
basal levels of nuclear Nrf2 protein in both cell types required long
film exposures, raising a concern that much higher Nrf2 levels in
SF- or tBHQ-treated samples were not accurately quantified. To
address this possibility, band densitometry was also performed on
short exposure films from the same experiments and showed
essentially the same results [Supplemental Fig. S5].) Interestingly,
tBHQ-induced activation of Nrf2 pathway was comparable to SF-
induced activation following 8 h treatment (Figs. 7D and S5-A),
but less strong following 16 h treatment (Figs. 7E and S5-B) in
both cell types. Taken together, the data indicate that both the
overall activity of Nrf2 pathway and expression level of many
Nrf2-regulated antioxidant and detoxifying enzymes are decreased
in CRI-G1-RS cells; these genetic changes are likely to mediate (or
at least contribute to) increased vulnerability to mitochondrial and
oxidative stress seen in these cells.
Another important antioxidant gene that showed high differ-
ential expression in the microarray dataset is aldehyde dehydro-
genase 2 (Aldh2; log2fold change=22.61, p-value=2.55610
218).
Aldh2 plays a key role in the metabolism of ethanol (by catalyzing
oxidation of acetaldehyde into acetic acid) and toxic aldehydes
such as 4-HNE, which at baseline (but not after oxidant treatment)
showed higher immunoreactivity in RR than RS cells (Fig. 4A). In
addition, Aldh2 is one of key mediators of the cardiac ischemic
preconditioning [33]. Interestingly, a dominant negative mutation
of Aldh2 (Aldh2*2), common in Asian populations, leads to
alcohol intolerance and increased risk of Alzheimer disease,
particularly in ApoE4 carriers [34]; it is not currently known
whether it also raises the risk for diabetes or other age and
oxidative stress-associated diseases. Expression of Aldh2*2 in cell
lines results in increased vulnerability to mitochondrial toxins [35];
in transgenic mice, it leads to age-dependent neurodegeneration
accompanied by memory loss [36]. To confirm that observed
changes in Aldh2 mRNA levels lead to differences in Aldh2
protein expression in CRI-G1 cells, whole cell lysates from
untreated RR and RS cells were immunoblotted with anti-Aldh2
antibody (Fig. 8A). Consistent with mRNA expression data, we
found that Aldh2 protein was strongly expressed in RR cells but
barely detectable in RS cells (84% or ,6 fold decrease; n=6,
p,0.0001). While expression of many aldehyde dehydrogenases is
regulated by Nrf2 [37,38], the data for Aldh2 (derived mostly from
microarray experiments) are currently equivocal: it was reported
that Nrf2 does not regulate either basal or inducible Aldh2
expression [38], that it regulates basal Aldh2 expression only [39],
and that it regulates both basal and inducible Aldh2 expression
[40]. To determine whether Nrf2 pathway upregulation leads to
an increase in Aldh2 expression in the CRI-G1 cell line, we used
immunoblotting to measure Aldh2 protein levels following
treatment of both RR and RS cells with vehicle (0.2% DMSO),
5 mM SF, or 10 mM tBHQ for 24 hours (Fig. 8B). While Aldh2
protein levels were significantly different between RR and RS cells
(two-way ANOVA, n=5; p,0.0001), as seen with untreated
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PLoS ONE | www.plosone.org 9 January 2011 | Volume 6 | Issue 1 | e14485samples (Fig. 8A), neither SF nor tBHQ treatment resulted in
Aldh2 upregulation in either cell type (p=0.28). The same result
was seen with shorter (8 h; Supplemental Fig. S6) and longer
treatments (up to 48 h; data not shown). Taken together, the data
indicate that decreased expression of Aldh2, which most likely is
not regulated by Nrf2 in this cell type, represents another potential
mechanism for increased vulnerability to mitochondrial dysfunc-
tion seen in CRI-G1-RS cells.
Figure 6. Differential expression of genes in the canonical Nrf2-mediated oxidative stress response pathway. Genes are represented as
nodes, biological relationships between two nodes as lines. The intensity of the node color indicates the degree of up- (red) or down- (green)
regulation in CRI-G1-RS cells relative to CRI-G1-RR cells; gray node color indicates genes showing no differential expression between RR and RS cells,
while white node color marks genes that were not present on the array. Protein complexes/gene groups are indicated by nodes with double outlines;
color shading within such a node indicates that genes within the complex/gene group showed different expression changes. The analysis was
performed on 3917 probes with FDR-adjusted p-value#0.001, regardless of the fold change. When multiple probes were present for a single gene,
the probe with the smallest p-value was used.
doi:10.1371/journal.pone.0014485.g006
Figure 7. Differential expression of Nrf2, Keap1, and DJ-1. A. At baseline, Nrf2 protein level (apparent MW, 77 kDa) in the nuclear fraction is
significantly lower in CRI-G1-RS than RR cells. B. At baseline, Keap1 protein level (apparent MW, 69 kDa) in the whole cell lysate is significantly higher
in CRI-G1-RS than RR cells. C. At baseline, DJ-1 protein level (apparent MW, 21 kDa) in the whole cell lysate is significantly lower in CRI-G1-RS than RR
cells. D and E. Treatment with 5 mMS Fo r1 0mM tBHQ for 8 h (D)o r1 6h( E) activated Nrf2 pathway to a similar extent in both CRI-G1-RR and RS
cells. Apparent MW for lamin A was 68 kDa; for tubulin, 51 kDa. In panels A–C, statistical significance was determined by two-tailed Student’s t-test;
scatter plots of all data points are shown. In panels D and E, statistical significance was determined by two-way ANOVA; data are plotted as mean 6
S.E.M. (n=5). While there was no statistically significant difference between the two cell types overall, ad-hoc Bonferroni post-tests detected a
statistically significant difference between DMSO-treated RR and RS samples (p,0.01), similar to the difference observed with untreated samples
(panel A). *, p,0.05; ***, p,0.001.
doi:10.1371/journal.pone.0014485.g007
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differentiation/function and in glucose-sensitive insulin
secretion
The top Physiological System Development and Function Gene Network
identified by IPA was Endocrine System Development and
Function cluster (p-value range 0.0002 to 0.05), which includes
networks with overlapping sets of genes, such as Quantity of b Islet
Cells, Size of Islet Cells, Proliferation of b Islet Cells, Differen-
tiation of Pancreatic Cells, and Degranulation of b Islet Cells
(among others). To illustrate gene expression changes in genes
important for b cell differentiation and function, 24 genes that
belong to these pathways and show differential expression between
CRI-G1-RR and RS cells were compiled in a single IPA-created
schematic diagram (Fig. 9; larger version is provided as
Supplemental Fig. S7). Interestingly, we found that many
transcription factors that are required for specification and/or
maintenance of b cell fate, such as Neurod1, Pax4, Pdx1, Nkx6-1,
and Nkx2-2 [41], were significantly upregulated in oxidative stress-
susceptible CRI-G1-RS cells. Expression of b cell-specific genes,
such as insulin 1, insulin 2 and glucokinase [42], was also much
higher in CRI-G1-RS cells. (The differential expression of many of
these genes was confirmed by qRT-PCR; Table 1.) We thus also
examined whether there was a difference in glucose sensitivity and
insulin release between oxidant-resistant RR and oxidant-sensitive
RS cells (Fig. 10). As described in the original report [16], CR1-
G1-RR cells secreted little insulin at baseline (11.363.1 ng/mL
per 1 ng DNA; n=4) and did not show significant increase in
insulin secretion in response to 20 mM glucose (22.964.8 ng/mL
per 1 ng DNA; n=4, p.0.05; Fig. 10A). In contrast, oxidant-
susceptible RS cells showed significant increase in insulin secretion
following the high glucose stimulus (330.5685.1 ng/mL vs.
124.0624.0 ng/mL per 1 ng DNA; n=4, p,0.05). Interestingly,
baseline content of intracellular insulin was slightly lower in RS
cells than in RR cells (34.167.3 vs. 80.1616.0 ng/mL per 1 ng
DNA respectively; n=4, p,0.05; Fig. 10B). Given that RS cells
express higher level of both Ins1 and Ins2 mRNA (Table 1), the
reason for this difference is not clear; one possibility is that chronic
secretion induced by maintenance media (which contains 25 mM
glucose) resulted in relative insulin depletion that did not
completely recover during 3 h incubation in 0 mM glucose (see
Materials and Methods for details of insulin ELISA). Following
stimulation with high glucose, there was no significant difference in
the intracellular insulin content between the two cell types
(56.665.5 ng/mL per 1 ng DNA in RR cells vs. 45.4612.8 ng/
mL per 1 ng DNA in RS cells; n=4, p.0.05). Taken together, the
data raise a possibility that CRI-G1-RS cell line corresponds to a
more differentiated b cell phenotype and support the recent
hypothesis that increased expression of antioxidant enzymes can
lead to glucose resistance [43].
Discussion
Many age-associated disorders (including diabetes, cancer, and
neurodegenerative diseases) are associated with oxidative stress
and mitochondrial dysfunction; at least in part, this may reflect
accumulation of mitochondrial genome mutations that occurs with
aging [1]. Pancreatic b cells express very low levels of antioxidant
enzymes [44] and are particularly vulnerable to mitochondrial
dysfunction and oxidative stress, which are thought to significantly
contribute to pathogenesis of both type 1 and type 2 diabetes
[4,45,46]. Here, we show that increased vulnerability to
mitochondrial dysfunction and oxidative stress in an insulinoma
cell line is associated with (1) morphologic change to a flat, surface-
adherent phenotype accompanied by gene expression changes in
integrin/FAK signaling pathways (Supplemental Figs. S8 and S9);
(2) increased expression of b cell-specific genes and transcription
factors that specify/maintain b cell fate; (3) restored GSIS; (4)
downregulation of ARE/Nrf2/Keap1 antioxidant pathway; (5)
decreased expression of antioxidant and phase I/II conjugation
enzymes, many of which belong to the Nrf2 pathway; and (6)
increased expression of molecular chaperones, many of which,
interestingly, also belong to the Nrf2 pathway.
Figure 8. Differential expression of Aldh2 at baseline and following activation of Nrf2 pathway. A. At baseline, Aldh2 protein level
(apparent MW, 51 kDa) in the whole cell lysate is significantly lower in CRI-G1-RS than in CRI-G1-RR cells. Statistical significance was determined by
two-tailed Student’s t-test; scatter plot of all data points is shown. B. Aldh2 expression was not affected by 24 h treatment with 5 mMS Fo r1 0mM
tBHQ (two activators of Nrf2 pathway) in either cell type; regardless of the treatment, Aldh2 expression level was significantly lower in CRI-G1-RS than
in CRI-G1-RR cells. Statistical significance was determined by two-way ANOVA; data are plotted as mean 6 S.E.M. (n=5). ***, p,0.001.
doi:10.1371/journal.pone.0014485.g008
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PLoS ONE | www.plosone.org 12 January 2011 | Volume 6 | Issue 1 | e14485Given the important role of Nrf2 pathway in susceptibility to
oxidative stressors and mitochondrial toxins in other cell types, it is
likely that downregulation of Nrf2-regulated antioxidant and/or
phase II conjugating enzymes significantly contributes to increased
vulnerability of CRI-G1-RS cells to mitochondrial and oxidative
stress, although additional experiments will be required to test this
hypothesis. Many questions remain, however. Which Nrf2 target
genes are primarily responsible for the observed differences in
oxidant and mitochondrial toxin vulnerability? Do Nrf2-indepen-
dent antioxidant genes, such as Aldh2, contribute to the observed
phenotype? What mechanisms mediate upregulation of Nrf2-
dependent molecular chaperons in the setting of a global
downregulation of Nrf2 pathway? Perhaps most importantly, is
there a causal relationship between different changes we observed
and – if there is – what is the direction of causality? Further work
will be required to answer these questions. However, the gene
expression changes we uncovered raise several interesting
possibilities.
First, downregulation of Nrf2 pathway in RS cells may be
secondary to the lower oxidative stress these cells show at baseline
(Fig. 4A); this possibility is supported by the fact that, despite
baseline differences in Nrf2 activity, induced Nrf2 response did not
significantly differ between the two cell types (Fig. 7). Basal
activation of Nrf2 pathway in RR cells would thus represent a
hormetic response, where a low dose of a toxic agent results in
induction of a beneficial response that protects against a larger
dose of the same agent [47]. It is not clear, however, what
molecular changes in RR cells underlie the pro-oxidant baseline
state observed in this cell type. Second, it is possible that
downregulation of Nrf2 pathway and consequent decrease in
antioxidant enzyme expression are part of the b cell differentiation
program; this hypothesis is consistent with the long-established but
unexplained fact that mature b cells express antioxidant enzymes
at a much lower level than other cell types. Interestingly, it was
recently reported that suppression of KATP channel activity
protects murine pancreatic b cells against oxidative stress through
upregulation of antioxidant enzymes superoxide dismutase,
glutathione peroxidase and catalase [48], but the mechanism
underlying these antioxidant enzyme expression changes was not
identified. In our microarray dataset, there was a small but
statistically significant upregulation of Kcnj11 (pore-forming Kir6.2
subunit of the b cell KATP channel) in oxidant-vulnerable CRI-
G1-RS cells, which was associated with increased KATP current
density in this cell type (unpublished preliminary data). The data
presented here are thus consistent with a model, which we are
currently testing, that an increase in the plasma membrane KATP
current (which is associated with b cell differentiation [42]) inhibits
Nrf2 pathway activity and downregulates antioxidant enzyme
expression, resulting in a greater vulnerability to metabolic and
oxidative stress. If true, this mechanism would have implications
beyond b cells and diabetes; for example, deletion of Kir6.2
protects substantia nigra dopaminergic neurons against cell death
induced by chronic treatment with MPTP (Parkinsonian neuro-
toxin and mitochondrial complex I inhibitor [49]), but the
molecular mechanism underlying this phenomenon is not well
understood. Third, downregulation of Nrf2 pathway may be
downstream of integrin/FAK signaling. Flat, surface-adherent
Figure 9. Differential expression of genes important for b cell differentiation and function. Genes are represented as nodes, biological
relationships between two nodes as lines. The intensity of the node color indicates the degree of up- (red) or down- (green) regulation in CRI-G1-RS
cells relative to CRI-G1-RR cells; the analysis was performed with 3917 probes with FDR-adjusted p-value#0.001, regardless of the fold change. When
multiple probes were present for a single gene, the probe with the smallest p-value was used.
doi:10.1371/journal.pone.0014485.g009
Figure 10. Differences in glucose-induced insulin secretion and
intracellular insulin content. A. Insulin secretion is induced by
20 mM glucose in RS but not in RR cells. B. Intracellular insulin content
is modestly but significantly lower in RS than RR cells at 0 mM glucose;
there is no difference between the two cell types following the high
glucose challenge. Statistical significance was determined by two-way
ANOVA followed by ad-hoc Bonferroni post-tests (n=4); all data are
plotted as mean 6 S.E.M. *, p,0.05; ***, p,0.001.
doi:10.1371/journal.pone.0014485.g010
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associated with gene expression changes in integrin/FAK signaling
pathways (Supplemental Figs. S8 and S9). Integrin clustering and
recruitment of FAK to focal adhesions result in activation of
multiple downstream signaling cascades including pro-survival
PI3K/Akt pathway, which can activate Nrf2 signaling [50,51];
thus, increased cell adherence would be predicted to result in
upregulation, not downregulation, of Nrf2 pathway. However, we
observed no change in levels of total Akt or phosphorylated (active)
Akt between CRI-G1-RR and CRI-G1-RS cells (Supplemental
Fig. S10). Further work will be required to establish whether
integrin/FAK signaling is indeed increased or decreased in CRI-
G1-RS cells and whether it plays an important role in the
regulation of Nrf2 pathway.
What is the physiologic and pathophysiologic role of Nrf2
signaling in b cells? Oxidative stress is thought to play a
significant role in the pathogenesis of both type 1 and type 2
diabetes; thus, the low expression level of antioxidant enzymes
in b cells – possibly reflecting the low basal activity of Nrf2
pathway, as in CRI-G1-RS cell line – renders these cells
vulnerable to the oxidant-induced cell death. Indeed, upregula-
tion of endogenous antioxidant enzymes protects b cells against
H2O2-induced cell death in vitro and streptozotocin-induced b
cell destruction in vivo [ 4 8 ] ,a n dw a st h u sp r o p o s e da sa
promising strategy for treatment and/or prevention of diabetes.
However, ROS derived from glucose metabolism also act as a
signal in GSIS [9]; by blunting glucose-mediated ROS
production, upregulation of endogenous antioxidant defenses
might compromise b cell function [43]. For example, overex-
pression of H2O2-scavenging enzymes catalase and glutathione
peroxidase actually sensitizes mice to insulin resistance and
diabetes [52,53]. In this context, it is interesting that downreg-
ulation of endogenous antioxidant defenses in CRI-G1 cells was
accompanied by increased expression of markers of b cell
differentiation (Fig. 9) and reconstitution of GSIS (Fig. 10). It will
thus be important to directly examine the effect of Nrf2 pathway
activation on GSIS and other aspects of b cell function. More
generally, the role of ROS in cellular signaling may limit the
physiologic range of antioxidant enzyme expression levels in
neuroendocrine cells, thus rendering them particularly vulnera-
ble to oxidative stress. Consistent with this idea, glutathione
concentration in neurons is low [54,55] and activation of Nrf2
pathway in the brain, while neuroprotective, primarily occurs in
astrocytes [56]. Importantly, ARE/Keap1/Nrf2 pathway regu-
lates the expression of a large battery of antioxidant and phase I/
II conjugation enzymes. By elucidating the effect of individual
Nrf2 target genes on (1) b cell and/or neuronal signaling and (2)
cell survival, it may be possible to identify individual genes or
pathways that decrease oxidative stress vulnerability without
interfering with cell function and thus constitute better
therapeutic targets than the Nrf2 pathway as a whole.
In summary, we have isolated a novel CRI-G1-RS subclone of
the CRI-G1 insulinoma cell line that shows increased expression of
b cell differentiation markers, reconstitution of GSIS, decreased
activity of ARE/Keap1/Nrf2 pathway, and increased vulnerabil-
ity to mitochondrial dysfunction and oxidative stress compared to
the parental CRI-G1-RR cells. CRI-G1-RR and -RS cell lines
thus provide an excellent experimental model for testing of the
recently proposed hypothesis that activation of Nrf2 pathway
impairs glucose sensing and insulin release by b cells [43]. In
addition, the availability of these cell lines will facilitate
identification of individual genes and pathways that modulate
vulnerability to oxidative stress and thus represent potential
therapeutic targets for diabetes and neurodegenerative diseases.
Materials and Methods
Cell culture
CRI-G1 cell line was obtained from European Collection of
Cell Cultures and maintained in DMEM with GlutaMAX, 4.5 g/
L glucose, and 110 mg/L sodium pyruvate (Invitrogen) supple-
mented with 10% heat inactivated FBS (Omega Scientific) and
10 mg/mL penicillin/10 units/mL streptomycin (UCSF Cell
Culture Facility). Cells were initially passaged once a week,
allowing cultures to reach relatively high densities; those culturing
conditions foster changes in cell morphology and other properties
(see Results for additional details). After isolation of a novel CRI-
G1-RS subclone, both the original clone (renamed CRI-G1-RR
for clarity) and the novel subclone were grown at lower densities
and passaged twice a week. Under these conditions, the phenotype
of each cell line remained stable for .20 passages.
For imaging, cells were grown on glass coverslips (Bellco) coated
with poly-L-lysine (Sigma). Images were taken with a Retiga CCD
camera on an Olympus 1671 inverted DIC microscope using
QCapture 2.90.1 software (Quantitative Imaging Corp) and were
edited with Adobe Photoshop CS3 Version 10.0.1.
Drugs
Except for staurosporine and oligomycin, which were purchased
from Calbiochem, all drugs were obtained from Sigma-Aldrich.
Drugs were generally purchased in dry (powder) form, with stock
solutions prepared and stored in small aliquots at 220uC; the
exceptions were staurosporine (which was purchased as 1 mM
stock solution prepared in dymethylsulfoxide [DMSO]) and
xanthine oxidase (which was either dissolved fresh before each
experiment or prepared as a stock solution stored at 280uC).
Stock solutions were as follows: 10 mM rotenone (in DMSO);
20 mM antimycin (in DMSO); 10 mM oligomycin (in DMSO);
20 mM FCCP (carbonyl cyanide-p-trifluoromethoxyphenylhydra-
zone; in DMSO); 10 mM hypoxanthine (in water; heating to
,50uC was required for solubilization and re-solubilization after
thawing); 1 kU/L xanthine oxidase (in 50 mM K2HPO4,
pH=7.25); 2.5 mM L-sulforaphane (in DMSO); and 10 mM
tert-butylhydroquinone (tBHQ; in DMSO). Antimycin and oligo-
mycin are sold as mixtures of different isoforms, each with a
unique molecular weight. Molar concentration was thus calculated
based on the molecular weight of a dominant isoform (antimycin A
and oligomycin A respectively); the corresponding stock solution
mass concentrations were 11.0 mg/mL for antimycin and
7.9 mg/mL for oligomycin.
Viability and cytotoxicity assays
For cell viability/toxicity assays, cells were grown in a Phenol
Red-free media that was otherwise identical in composition to the
regular maintenance media. Cells were seeded on 96-well clear
(for colorimetric assay) or white (for luminescence assays) tissue
culture plates (1–2610
4 cells/well, 4 wells/condition) and treated
with drugs 18–24 h later. Drug solutions were prepared from stock
solutions and applied either at the final concentration (100 mL/
well) following aspiration of original plating media, or as a 20 mL
volume of a 56solution (prepared in media) without aspiration of
original plating media (for final volume of 100 mL). Viability and
toxicity assays were typically performed 18–24 hours later, but
longer treatments (up to 5 days) were done in some experiments.
Cell viability was determined by CellTiter 96 AQueous One
Solution Cell Proliferation Assay (Promega) according to the
manufacturer’s instructions. This assay measures the absorbance
of a formazan, which is generated by mitochondrial metabolism
and is directly proportional to the number of living cells in the
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TM Assay
(Promega) according to the manufacturer’s instructions; this assay
measures the activity of a ‘‘dead-cell’’ protease released into the
media from membrane-compromised cells. Apoptosis was deter-
mined by measuring activity of caspases 3 and 7 with Caspase-
Glo
TM 3/7 Assay (Promega) according to the manufacturer’s
instructions, except that cell lysis was performed in 50 mL (instead
of 100 mL) of culture media to minimize the reagent use. Data
were analyzed with GraphPad Prism statistical software using two-
way ANOVA followed by ad-hoc Bonferroni post-test.
RNA preparation, microarray hybridization and data
analysis
Total RNA was isolated using RNeasy Kit (Qiagen) with
contaminating genomic DNA removed during the isolation by an
on-column DNase digestion step; six independent replicates were
prepared from each cell type. cDNA synthesis, RNA amplification,
biotin labeling, and aRNA fragmentation were performed using
MessageAmpII Biotin Enhanced Single Round aRNA Amplifica-
tion Kit (Ambion) according to the manufacturer’s instructions.
The quality and/or size distribution of total RNA, aRNA, and
fragmented aRNA were evaluated by microfluidic gel electropho-
resis with a bioanalyzer (Agilent) prior to hybridization. Labeled
cRNA samples were hybridized to Affymetrix Rat 230 2.0 arrays,
stained, and scanned according to the manufacturer’s instructions.
All analyses were performed using the freely available R
language [57]. Array quality was analyzed using the affyPLM
package [58]. The data were normalized by a robust multi-chip
averaging method [59]. Limma package [60,61] in Bioconductor
[62] was used to fit a linear model with log2 expression as response
variable and cell type as the independent variable. P-values were
adjusted by controlling the false discovery rate [63]. A change in
gene expression was identified as significant if the false discovery
rate was less than 0.05, meaning that fewer than 5% of false
findings would be expected among the genes declared to be
differentially expressed. The raw image and processed expression
values for our dataset are posted in a MIAME-compliant format at
NCBI’s Gene Expression Omnibus database (accession number
GSE19948).
GOstat [23] was used to search for significant GO terms for the
significant genes with at least two fold change in expression. The
data were also analyzed using Ingenuity Pathways Analysis
(IngenuityH Systems, www.ingenuity.com). The Functional Anal-
ysis identified the biological functions that were most significant to
the data set. Molecules from the dataset that met the p-value cutoff
of 0.001 and were associated with biological functions in
Ingenuity’s Knowledge Base were considered for the analysis.
Right-tailed Fisher’s exact test was used to calculate a p-value
determining the probability that each biological function and/or
disease assigned to that data set is due to chance alone. Canonical
pathways analysis identified the pathways from the Ingenuity
Pathways Analysis library of canonical pathways that were most
significant to the data set. Molecules from the data set that met the
p-value cutoff of 0.001 and were associated with a canonical
pathway in Ingenuity’s Knowledge Base were considered for the
analysis. The significance of the association between the data set
and the canonical pathway was measured in 2 ways: 1) A ratio of
the number of molecules from the data set that map to the
pathway divided by the total number of molecules that map to the
canonical pathway; 2) Fisher’s exact test was used to calculate a p-
value determining the probability that the association between the
genes in the dataset and the canonical pathway is explained by
chance alone. Pathways are graphical representations of the
molecular relationships between molecules. Molecules are repre-
sented as nodes, and the biological relationship between two nodes
is represented as an edge (line). All edges are supported by at least
1 reference from the literature, from a textbook, or from canonical
information stored in the Ingenuity Pathways Knowledge Base.
Human, mouse, and rat orthologs of a gene are stored as separate
objects in the Ingenuity Pathways Knowledge Base, but are
represented as a single node in the network. The intensity of the
node color indicates the degree of up- (red) or down- (green)
regulation. Nodes are displayed using various shapes that
represent the functional class of the gene product.
qRT-PCR
Five independent biological samples of each cell type were used
for qRT-PCR analyses. Total RNA was isolated using RNeasy
Protect Mini Kit (Qiagen), with RNA integrity (28S/18S)
confirmed by running an aliquot of each sample on a 1% agarose
mini-gel. mRNA (1 mg/sample) was reverse transcribed to cDNA
using Taqman Reverse Transcription Reagents kit (Applied
Biosystems). qPCR reactions were carried out in an Opticon
DNA Engine 2 Continuous Fluorescence Detection System
(Biorad) using 10 ng sample in a 25 mL, 98-well format. TaqMan
universal PCR master mix and predesigned TaqMan PCR primer
and probe sets were purchased from Applied Biosystems for all
genes tested (Supplemental Table S2). Rat ACTB (actin, beta)
Endogenous Control FAM Dye/MGB Probe (Applied Biosystems)
was used for normalization. The common reference cDNA, used
to prepare the standard curve for all reactions, was generated by
mixing an equal amount of cDNA obtained from independent
biological replicates of each cell type. Three technical replicates for
each sample were run on one plate and 2 replicate plates were
performed for each gene; thus, a total of 6 technical replicates were
performed for each sample and each gene. For analysis, all 6
values were averaged, with mean used for subsequent statistical
analysis performed with GraphPad Prism statistical software using
two-tailed Student’s t-tests.
Western blotting
Whole cell lysates were prepared by incubating resuspended cell
pellets in RIPA lysis buffer (0.5% sodium deoxycholate, 0.1%
sodium dodecylsulfate, 1% Triton X-100, 150 mM NaCl, 50 mM
TrisCl, 1 mM EDTA; pH=7.4) supplemented with Complete
TM
Protease Inhibitor Cocktail (Roche) for 15 min on ice; crude
lysates were centrifuged (15,000 g for 10 min at 4uC) to remove
insoluble/particulate matter. Nuclear and cytoplasmic fractions
were prepared using the NE-PER kit (Pierce) according to the
manufacturer’s instructions. The protein concentration of each
sample was assayed relative to the bovine serum albumin (BSA)
standard with the CBB Assay kit (Dojindo); approximately 25 mg
of total protein was eventually loaded in each lane. After
solubilization with LDS sample buffer (Invitrogen) supplemented
with TCEP reducing reagent (Pierce; final concentration 12 mM),
samples were heated for 10 min at 70uC, electrophoretically
resolved with 10% or 4–12% (for Nrf2) NuPAGE precast gels
(Invitrogen), and electroblotted to nitrocellulose membranes (0.2 A
for 5 hours at 4uC). Three percent nonfat dried milk in TBS
(150 mM NaCl, 20 mM Tris Cl; pH=7.4) was used for blocking,
washing, and dilution of primary and secondary antibodies, except
for DJ-1, Akt and P-Akt where primary antibody incubation was
performed in TBS supplemented with 5% w/v BSA and 0.1%
Tween. Membranes were blocked for 1 h at room temperature
(RT); incubated with primary antibodies for 2 h at RT (Keap1,
COXIV, cytochrome c, tubulin, tom20 and lamin A), 2–4 h at RT
(Nrf2), or overnight at 4uC (DJ-1, Akt and P-Akt); washed for 1 h
at RT; incubated with corresponding secondary antibody for 1 h
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TBS with 0.1% Tween for 15 min at RT and a water rinse,
protein-antibody complexes were detected using an ECL chemi-
luminescent kit (Pierce Biotechnology) and CL-XPosure Film
(Thermo Scientific) with a Konica SRX-101A developer.
The following primary antibodies were used: rabbit polyclonal
anti-PARK7/DJ-1, 1 mg/mL (GenWay Biotech); mouse mono-
clonal anti-Keap1, 1 mg/mL (ProteinTech Group); mouse mono-
clonal anti-COXIV 20E8, 0.1 mg/mL (Abcam); mouse monoclo-
nal anti-cytochrome c, 0.5 mg/mL (BD Pharmingen); rabbit
polyclonal anti-Tom20 FL-145, 0.07 mg/mL, and rabbit poly-
clonal Nrf2 H300, 0.5 mg/mL (Santa Cruz Biotechnology); rabbit
polyclonal anti-Aldh2, 1:10000 (gift of Dr. Henry Weiner, Purdue
University); rabbit polyclonal anti-Akt and anti-phospho-Akt,
1:1000 (Cell Signaling); mouse monoclonal anti-tubulin clone
DM1A (ascites fluid), 1 mg/mL, and rabbit polyclonal anti-lamin
A C-terminal, 1 mg/mL (Sigma). Horseradish peroxidase-conju-
gated anti-mouse and anti-rabbit secondary H+L IgG antibodies
were purchased from Jackson ImmunoResearch; anti-mouse
antibody was used at 0.8 mg/mL, while anti-rabbit antibody was
used at either 8 mg/mL (for anti-PARK7/DJ-1 and anti-Nrf2) or
0.8 mg/mL (for anti-Tom20, anti-Aldh2, anti-Akt, anti-P-Akt. and
anti-lamin A).
ImageJ software (http://rsb.info.nih.gov/ij/) was used for band
quantification by densitometry. Data were analyzed with Graph-
Pad Prism statistical software using two-tailed t-test (for compar-
ison of baseline protein levels) or two-way ANOVA with ad hoc
Bonferroni post-test (for comparison of drug treatment effects
between the two cell types).
4-HNE immunostaining
Cells were grown overnight on poly-L-lysine-coated glass
coverslips, incubated with hypoxanthine (0.5 mM)/xanthine
oxidase (16 U/L) for 1 hour, washed once with PBS, and fixed
in 4% formaldehyde 4% sucrose in PBS for 15 minutes at room
temperature; coverslips were stored in PBS at 4uC until
immunostaining. Cells were blocked in PBS with 0.1% Triton-X
and 5% normal goat serum for 1 hour at room temperature,
incubated in blocking solution with 4 mg/mL rabbit anti-4-HNE
(Alpha Diagnostic) at 4uC overnight, washed 3 times in PBS with
0.1% Triton-X, and incubated in blocking solution with 2 mg/mL
Alexa Fluor 488-conjugated goat anti-rabbit IgG (H+L; Invitro-
gen) for 2 hours at room temperature. Coverslips were mounted
on glass slides with Vectashield mounting medium containing
DAPI nuclear counter stain (Vector Laboratories). Images were
taken with Zeiss LSM 510 imaging software (version 4.2) using
206 and 636 objectives on Zeiss LSM 510 NLO confocal
microscope; they were edited with Adobe Photoshop CS3 Version
10.0.1.
Glutathione measurement
The concentration of reduced (GSH) and total (GSH+GSSG)
glutathione was determined using the GSH-Glo
TM Glutathione
Assay kit (Promega) according to the manufacturer’s instructions;
this luminescence-based assay is based on the conversion of a
luciferin derivative into luciferin, catalyzed by glutathione S-
transferase in the presence of glutathione. Frozen cell pellets were
resuspended in 200 mL ice-cold phosphate-buffered saline supple-
mented with Complete
TM Protease Inhibitor Cocktail (Roche).
10 mL aliquot of each cell suspension (3 technical replicates/
sample) was used to measure GSH. Total glutathione was
measured by adding reducing agent TCEP (Pierce; 1 mM final
concentration) to 3 separate aliquots of each suspension to convert
GSSG to GSH prior to GSH measurement; the amount of TCEP
added did not significantly alter the total volume. Readings were
then normalized to protein concentration measured by CBB kit
(Dojindo) in a lysate prepared from an aliquot of each cell
suspension (as described for whole cell lysate in the Western
blotting section). The amount of GSSG in the sample was
calculated by halving the difference between the total and reduced
glutathione; two RS cell samples that had negative/undetectable
GSSG levels were excluded from the GSH/GSSG ratio analysis.
Data were analyzed with GraphPad Prism statistical software
using two-way ANOVA followed by ad-hoc Bonferroni post-tests.
Insulin ELISA
Cells were plated in a 12-well dish (5610
4 cells/well). The next
day, cells were washed twice with KRBB 2% BSA (Krebs-Ringer
Bicarbonate Buffer – 130 mM NaCl, 5 mM KCl, 1.25 mM
KH2PO4, 1.25 mM MgSO4, 2.68 mM CaCl2, 5.26 mM NaH-
CO3,10 mM HEPES; pH=7.4), incubated in KRBB 2% BSA at
37uC for 3 h, and then incubated in KRBB 2% BSA with or
without 20 mM glucose for 30 min; the supernatant from 30 min
incubation, which contained the secreted insulin, was collected,
spun down to remove debris, and stored in aliquots at 280uC. To
measure residual intracellular insulin, cells that remained in the
dish were scraped, pelleted, and lysed in 200 mL acid ethanol
(0.2 M HCl in 75% ethanol) overnight at 4uC. The lysate was
spun down to remove debris, neutralized with 0.2 M NaOH,
aliquoted, and stored at 280uC. Insulin was measured using the
Rat/Mouse Insulin ELISA kit (Millipore); values for both secreted
and intracellular insulin were normalized to the total DNA content
(measured by DNA spectrometry) in each lysate. Data were
analyzed with GraphPad Prism statistical software using two-way
ANOVA followed by ad-hoc Bonferroni post-tests.
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